Amphastar Pharmaceuticals Stock News

State of Alaska Department of Revenue raised its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 6.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 26,978 shares of the companys stock after buying an additional 1,600 shares during the []

It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Amphastar Pharmaceuticals (AMPH), AMN Healthcare (AMN) & Sensus Healthcare (SRTS) are well poised to gain.

Equities research analysts expect that Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) will announce sales of $111.62 million for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Amphastar Pharmaceuticals earnings, with estimates ranging from $109.00 million to $116.39 million. Amphastar Pharmaceuticals reported sales of $95.92 million during the same quarter last year, []

UBS Asset Management Americas Inc. raised its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 6.6% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 43,811 shares of the companys stock after purchasing an additional 2,724 shares during the quarter. UBS Asset Management []

RANCHO CUCAMONGA, CA / ACCESSWIRE / November 22, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate Commun

(PR-inside.com) RANCHO CUCAMONGA, CA / ACCESSWIRE / November 22, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate Communications, Tony Marrs, Sr. V.P Regulatory Affairs and Clinical Operations, and Jacob Liawatidewi, Executive V.P. Corporate Administration Center and Sales & Marketing, participated in an Analyst-Moderated fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference. This presentation will be made available November 22, 2021 at 10:00 am Eastern Standard Time. For access, visit Amphastar''s Pharmaceuticals website at http://ir.amphastar.com . This webcast will be available for 90 days following the presentation. About ..

RANCHO CUCAMONGA, CA / ACCESSWIRE / November 22, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate Communications, Tony Marrs, Sr. V.P Regulatory Affairs and

RANCHO CUCAMONGA, CA / ACCESSWIRE / November 22, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate Communica

RANCHO CUCAMONGA, CA / ACCESSWIRE / November 11, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate Communica

Amphastar Pharmaceuticals, Inc. (AMPH) Management on Q3 2021 Results - Earnings Call Transcript

Amphastar (AMPH) delivered earnings and revenue surprises of 109.09% and 8.93%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Amphastar Pharmaceuticals (NASDAQ:AMPH) reported its Q3 earnings results on Monday, November 8, 2021 at 04:00 PM. Here's what investors need to know about the announcement.

Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

RANCHO CUCAMONGA, CA / ACCESSWIRE / October 28, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2021 ended September 30, 2

RANCHO CUCAMONGA, CA / ACCESSWIRE / September 2, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate Communica